Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Ca

• Status: Active, not recruiting
• Trial end date: 1969-12-31

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen-deprivation therapy is more effective for prostate cancer.

PURPOSE: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Radiation Therapy Oncology Group
• Collaborators: Cancer and Leukemia Group B; National Cancer Institute (NCI); NRG Oncology
• Treatments: Androgens; Bicalutamide; Buserelin; Flutamide; Goserelin; Leuprolide; Triptorelin Pamoate